Abstract
To assess molecular evolution of the respiratory syncytial virus (RSV) fusion gene, we analyzed RSV-positive specimens from 123 children in Canada who did or did not receive RSV immunoprophylaxis (palivizumab) during 2006-2010. Resistance-conferring mutations within the palivizumab binding site occurred in 8.7% of palivizumab recipients and none of the nonrecipients.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Canada / epidemiology
-
Cohort Studies
-
Evolution, Molecular*
-
Gene Expression Regulation, Viral / physiology
-
Humans
-
Respiratory Syncytial Virus Infections / epidemiology
-
Respiratory Syncytial Virus Infections / virology*
-
Respiratory Syncytial Viruses / genetics*
-
Viral Fusion Proteins / genetics
-
Viral Fusion Proteins / metabolism*